Showing results (491-500 of 536) with videos related to
Sort By:
Pageof 54
Cardiovascular Diabetology|November 20, 2024
Lipoxin A4 improves cardiac remodeling and function in diabetes-associated cardiac dysfunctionTing Fu, Muthukumar Mohan, Madhura Bose, et al.Clinical Journal of the American Society of Nephrology : CJASN|August 21, 2007
Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL studyWilliam F Keane, Zhongxin Zhang, Paulette A Lyle, et al.Diabetes Care|March 24, 2016
Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ONMuh Geot Wong, Vlado Perkovic, John Chalmers, et al.Clinical Science (London, England : 1979)|August 28, 2012
Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetesMona Sedeek, Alex Gutsol, Augusto C Montezano, et al.Diabetes|June 29, 2004
Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosisJosephine M Forbes, Louis Teo Loon Yee, Vicki Thallas, et al.Diabetology International|March 25, 2020
Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trialNobuya Inagaki, Wenying Yang, Hirotaka Watada, et al.Journal of the American Society of Nephrology : JASN|January 23, 2009
RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetesMelinda T Coughlan, David R Thorburn, Sally A Penfold, et al.The American Journal of Clinical Nutrition|April 1, 2016
Diet low in advanced glycation end products increases insulin sensitivity in healthy overweight individuals: a double-blind, randomized, crossover trialBarbora de Courten, Maximilian Pj de Courten, Georgia Soldatos, et al.Diabetologia|May 7, 2020
Empagliflozin modulates renal sympathetic and heart rate baroreflexes in a rabbit model of diabetesCindy Gueguen, Sandra L Burke, Benjamin Barzel, et al.Clinical Kidney Journal|February 10, 2021
Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trialChristoph Wanner, Mark E Cooper, Odd Erik Johansen, et al.Pageof 54